569 related articles for article (PubMed ID: 15803876)
21. [Current status of the neo-adjuvant and adjuvant therapy for the resectable non-small cell lung cancer].
Yamaguchi M; Fukuyama Y; Ichinose Y
Gan To Kagaku Ryoho; 2003 Feb; 30(2):203-8. PubMed ID: 12610867
[TBL] [Abstract][Full Text] [Related]
22. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
Cerfolio RJ; Bryant AS; Jones VL; Cerfolio RM
Eur J Cardiothorac Surg; 2009 Apr; 35(4):718-23; discussion 723. PubMed ID: 19233668
[TBL] [Abstract][Full Text] [Related]
24. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
Takeda S; Maeda H; Okada T; Yamaguchi T; Nakagawa M; Yokota S; Sawabata N; Ohta M
Eur J Cardiothorac Surg; 2006 Jul; 30(1):184-9. PubMed ID: 16730452
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
26. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
[TBL] [Abstract][Full Text] [Related]
27. [On ''Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma: what is the answer?''].
González Aragoneses F
Arch Bronconeumol; 2007 Mar; 43(3):183-4; author reply 184. PubMed ID: 17386198
[No Abstract] [Full Text] [Related]
28. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
Mansour Z; Kochetkova EA; Santelmo N; Ducrocq X; Quoix E; Wihlm JM; Massard G
Ann Thorac Surg; 2008 Jul; 86(1):228-33. PubMed ID: 18573428
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A].
Mornex F
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S29-32. PubMed ID: 11924239
[No Abstract] [Full Text] [Related]
30. The role of multimodality therapy in locoregional non-small cell lung cancer.
Martini N; Kris MG; Ginsberg RJ
Surg Oncol Clin N Am; 1997 Oct; 6(4):769-91. PubMed ID: 9309093
[TBL] [Abstract][Full Text] [Related]
31. [The boundaries of curation].
Debus J; Eberhardt W; Hoffmann H; Passlick B; Rübe C; Thomas M
Onkologie; 2010; 33 Suppl 5():12-20. PubMed ID: 20523102
[TBL] [Abstract][Full Text] [Related]
32. Pneumonectomy after chemotherapy: morbidity, mortality, and long-term outcome.
Alifano M; Boudaya MS; Salvi M; Collet JY; Dinu C; Camilleri-Broët S; Régnard JF
Ann Thorac Surg; 2008 Jun; 85(6):1866-72; discussion 1872-3. PubMed ID: 18498785
[TBL] [Abstract][Full Text] [Related]
33. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
Uy KL; Darling G; Xu W; Yi QL; De Perrot M; Pierre AF; Waddell TK; Johnston MR; Bezjak A; Shepherd FA; Keshavjee S
J Thorac Cardiovasc Surg; 2007 Jul; 134(1):188-93. PubMed ID: 17599507
[TBL] [Abstract][Full Text] [Related]
34. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.
Meacci E; Cesario A; Cusumano G; Lococo F; D'Angelillo R; Dall'armi V; Margaritora S; Granone P
Eur J Cardiothorac Surg; 2011 Sep; 40(3):656-63. PubMed ID: 21402479
[TBL] [Abstract][Full Text] [Related]
35. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
36. Perioperative therapy for locoregional nonsmall-cell lung cancer.
Takita H
J Surg Oncol; 1996 May; 62(1):65-74. PubMed ID: 8618405
[TBL] [Abstract][Full Text] [Related]
37. Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer.
Fujita S; Katakami N; Takahashi Y; Hirokawa K; Ikeda A; Tabata C; Mio T; Mishima M
Eur J Cardiothorac Surg; 2006 Jun; 29(6):896-901. PubMed ID: 16675259
[TBL] [Abstract][Full Text] [Related]
38. [RAdio-chemo-surgical combined treatment of non-small cell lung carcinoma N2].
Rovea P; Sola B; Boidi Trotti A; Gabriele AM; Fracchia F; Casadio C; Bretti S
Radiol Med; 1993 Jun; 85(6):840-3. PubMed ID: 8393206
[TBL] [Abstract][Full Text] [Related]
39. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
[TBL] [Abstract][Full Text] [Related]
40. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors.
Paul S; Mirza F; Port JL; Lee PC; Stiles BM; Kansler AL; Altorki NK
J Thorac Cardiovasc Surg; 2011 Jan; 141(1):48-58. PubMed ID: 21092990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
